DUBLIN--(BUSINESS WIRE)--The "Left Ventricular Dysfunction - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Left Ventricular Dysfunction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Left Ventricular Dysfunction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Phase II stages are 3 and 4 respectively.
Left Ventricular Dysfunction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Report Coverage
- Left Ventricular Dysfunction - Overview
- Left Ventricular Dysfunction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Left Ventricular Dysfunction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Left Ventricular Dysfunction - Companies Involved in Therapeutics Development
- Bayer AG
- Innopharmax Inc
- Mesoblast Ltd
- Novartis AG
- Quantum Genomics SA
- TiGenix NV
